Based on the phase 2 and phase 3 trial protocols: Weeks 1-4: 1 mg once weekly Weeks 5-8: 2 mg once weekly Weeks 9-12: 4 mg once weekly Weeks 13-16: 8 mg once weekly Weeks 17 onward: 12 mg once weekly (maximum dose) The starting dose of retatrutide is deliberately low because the triple-agonist mechanism produces more intense initial side effects than single-pathway compounds
By restoring these fundamental communication pathways, GHK-Cu helps reset cellular functions, leading to healthier tissue, calmer inflammation, and a more robust internal repair system
Mikus, D., Grabarevic, Z., Rucman, R., Petek, M., Turkovic, B., Rokotov, D
It plays a pivotal role in various biological processes, including wound healing, tissue regeneration, and skin health
Gorouhi, F